M.D (Pharmacology), GIMS, Gulbarga, Karnataka, India

M.D (General Medicine), GIMS, Gulbarga, Karnataka, India
Diabetes mellitus ,Metformin ,Glibenclamide ,

Background: In the present world, many persons are suffering from diabetes mellitus, a common non-communicable disease, many a times remains undiagnosed and affecting various vital organs. It may be caused due to genetic or non-genetic abnormalities, environmental factors, infections, surgery, tumors, obesity, hormonal imbalance and many more. In the treatment of type 2 diabetes mellitus, our aim will be to maintain the normoglycemia throughout the time. To achieve this, we use different groups of drugs as single or multiple drug therapy. This study is taken to see the comparison of glibenclamide and combination of metformin and glibenclamide, for efficacy and tolerability. Objectives: To see the variations in the efficacy and tolerability of glibenclamide and combination of metformin and glibenclamide in type 2 diabetes mellitus. Materials and Methods: A total of hundred pateints with type 2 diabetes mellitus, coming to out patient department are taken for the study and divided into half glibenclamide group and half combination group. Medicine are given to different groups in their respective dose and dosage forms. Random blood glucose level was recorded in all subjects daily for one month using standard techniques. The data collected was analyzed statistically using descriptive statistics. Patient compliance was checked during follow up. Results: Results showed combination therapy has caused better reduction in blood glucose level (98% of subjects showed normoglycemia), than glibenclamide alone (58% of subjects showed normoglycemia) alone at the end of the study. Hyperglycemic episodes were less and but side effects were more in combination therapy. Patient compliance was satisfactory. Interpretation and Conclusion: Combination therapy of metformin and glibenclamide, controls the blood glucose level more precisely in comparison to glibenclamide alone in Type 2 DM.

9 , 1 , 2019